Prednisolone acetate steroid

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialise, actual results could vary materially from the expectations and projections of Janssen-Cilag International NV and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behaviour and spending patterns or financial distress of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 1, 2017, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at , or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies or Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

The correct dosage of prednisone and prednisolone depends on the condition being treated and how the patient responds to the medication. A rule of thumb for dosing prednisone and prednisolone is to use as much as is required but as little as possible to achieve the desired effect. Pets should also be weaned off of prednisone as soon as their condition allows. When dogs and cats have to be on prednisone for an extended period of time, giving the medication every other day or even less frequently if possible can reduce the chances of serious side effects. Common dosages for prednisone and prednisolone in dogs in cats are

The dosage and length of treatment with Pred Forte is based on the patient's medical condition and response to treatment. The usual dose is to instill one to two drops into the conjunctival sac two to four times daily. It is unlikely other drugs you take orally or inject will have an effect on Pred Forte used in the eyes. But many drugs can interact with each other. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor. During pregnancy, Pred Forte should be used only when prescribed. It is not known if the medication in this product passes into breast milk. Consult your doctor before breastfeeding.

NDC 61314-637-10

Prednisolone Acetate Ophthalmic Suspension USP 1%

Rx only

STERILE
10 mL

SANDOZ

FOR TOPICAL OPHTHALMIC USE ONLY.

INGREDIENTS: Each mL contains:
Active: prednisolone acetate %.
Preservative: benzalkonium chloride %.
Vehicle: hypromellose.
Inactives: dibasic sodium phosphate, polysorbate 80, edetate disodium, glycerin, citric acid and/or sodium hydroxide (to adjust pH), purified water.

USUAL DOSAGE: Two drops topically in the eye(s) four times daily.

WARNING: Do not touch dropper tip to any surface, as this may contaminate the suspension.

Read enclosed insert.

SHAKE WELL BEFORE USING.

STORAGE: STORE UPRIGHT at 8° - 24°C (46° - 75° F).

Manufactured by
Alcon Laboratories, Inc.
Fort Worth, Texas 76134 for
Sandoz Inc.
Princeton, NJ 08540
Printed in USA

H13438-0214

LOT/EXP.:

Prednisolone acetate steroid

prednisolone acetate steroid

NDC 61314-637-10

Prednisolone Acetate Ophthalmic Suspension USP 1%

Rx only

STERILE
10 mL

SANDOZ

FOR TOPICAL OPHTHALMIC USE ONLY.

INGREDIENTS: Each mL contains:
Active: prednisolone acetate %.
Preservative: benzalkonium chloride %.
Vehicle: hypromellose.
Inactives: dibasic sodium phosphate, polysorbate 80, edetate disodium, glycerin, citric acid and/or sodium hydroxide (to adjust pH), purified water.

USUAL DOSAGE: Two drops topically in the eye(s) four times daily.

WARNING: Do not touch dropper tip to any surface, as this may contaminate the suspension.

Read enclosed insert.

SHAKE WELL BEFORE USING.

STORAGE: STORE UPRIGHT at 8° - 24°C (46° - 75° F).

Manufactured by
Alcon Laboratories, Inc.
Fort Worth, Texas 76134 for
Sandoz Inc.
Princeton, NJ 08540
Printed in USA

H13438-0214

LOT/EXP.:

Media:

prednisolone acetate steroidprednisolone acetate steroidprednisolone acetate steroidprednisolone acetate steroidprednisolone acetate steroid